Skip to search boxSkip to navigationSkip to main content

Treatment Outcomes among Patients with a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study

  • Alex Soriano
    ,
  • Patrick M. Honore
    ,
  • Oliver A. Cornely
    ,
  • Methee Chayakulkeeree
    ,
  • Matteo Bassetti
    ,
  • Huang Haihui
*Corresponding author for this work
  • University of Barcelona
    ,
  • Centro de Investigación Biomédica en Red
    ,
  • CHU UCL Namur
    ,
  • University of Cologne
    ,
  • Mahidol University
    ,
  • University of Genoa
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

<p>Background: Rezafungin, a novel, once-weekly echinocandin for the treatment of candidemia and/or invasive candidiasis (IC) was noninferior to caspofungin for day 30 all-cause mortality (ACM) and day 14 global cure in the phase 3 ReSTORE trial (NCT03667690). We conducted preplanned subgroup analyses for patients with a positive culture close to randomization in ReSTORE. Methods: ReSTORE was a multicenter, double-blind, double-dummy, randomized trial in patients aged ≥18 years with candidemia and/or IC treated with once-weekly intravenous rezafungin (400 mg/200 mg) or once-daily intravenous caspofungin (70 mg/50 mg). This analysis comprised patients with a positive blood culture drawn between 12 hours before and 72 hours after randomization or a positive culture from another normally sterile site sampled between 48 hours before and 72 hours after randomization. Efficacy endpoints included day 30 ACM, day 14 global cure rate, and day 5 and 14 mycological response. Adverse events were evaluated. Results: This analysis included 38 patients randomized to rezafungin and 46 to caspofungin. In the rezafungin and caspofungin groups, respectively, day 30 ACM was 26.3% and 21.7% (between-group difference [95% confidence interval], 4.6% [-13.7%, 23.5%]), day 14 global response was 55.3% and 50.0% (between-group difference, 5.3% [-16.1%, 26.0%]), and day 5 mycological eradication was 71.1% and 50.0% (between-group difference, 21.1% [-0.2%, 40.2%]). Safety was comparable between treatments. Conclusions: These findings support the efficacy and safety of rezafungin compared with caspofungin for the treatment of candidemia and/or IC in patients with a positive culture close to randomization, with potential early treatment benefits for rezafungin.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 672-681 (10 pages)

Journal (Volume, Issue Number)

Clinical Infectious Diseases (Volume 79, Issue 3)

Publication milestones

  • Published - 09/15/2024

Publication status

Published - 09/15/2024

ISSN

1058-4838

Publication IDs

  • Scopus: 85205275022
  • PubMed: 38985561
  • ORCID: /0000-0001-5774-819X/work/227133140

Publication metrics

Metrics

Scopus
citations
Fractional count
1
Fractional count
0.06
Fractional count
16
Fractional count
0.94
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
7
Captures
19
Usage
89

Funding Details

The authors thank all patients and investigators involved in the study (as well as the members of the independent Data Review Committee). Medical writing support, including development of a draft outline and subsequent drafts in consultation with the authors, collating author comments, copyediting, fact checking, and referencing, was provided by Caroline Greenwood, BSc (Hons), CMPP, at Aspire Scientific Limited (Bollington, UK). Funding for medical writing support for this article was provided by Mundipharma (Cambridge, UK). The ReSTORE study was co-funded by Cidara Therapeutics and Mundipharma. Rezafungin is being developed by Cidara Therapeutics (San Diego, CA, USA) in partnership with Mundipharma (Cambridge, UK). Melinta Therapeutics (Parsippany, NJ, USA) holds the license to commercialize rezafungin in the United States. The analysis described in this manuscript was funded by Mundipharma.
FundersFunding numbers
Caroline Greenwood
-
Aspire Scientific Limited
-
Cidara Therapeutics and Mundipharma
-